Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced ALK-Positive NSCLC With or Without Baseline Central Nervous System Metastases

Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced ALK-Positive NSCLC With or Without Baseline Central Nervous System Metastases

Introduction: Alectinib was found to have superior efficacy to crizotinib in the phase 3 ALEX study and is a preferred initial treatment for patients with advanced ALK-positive NSCLC. To understand the efficacy of alectinib in U.S. clinical practice, we conducted a retrospective real-world comparati...

Full description

Bibliographic Details
Main Authors: Qing Zhang, PhD, Jessica J. Lin, MD, Navdeep Pal, M.B.B.S., MPH, Letizia Polito, PhD, Huong Trinh, MD, Magalie Hilton, MSc, Vlatka Smoljanović, MD, Nino Kurtsikidze, MD, Venice Archer, MD, Matthew G. Krebs, MD, PhD
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:JTO Clinical and Research Reports
Subjects:
Alectinib
Crizotinib
Real-world data
ALEX
Non–small cell lung cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S266636432300022X

Internet

http://www.sciencedirect.com/science/article/pii/S266636432300022X

Similar Items